Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Phase II Multicenter Study of Rituximab or Tocilizumab for Steroid-Dependent Immune-Related Adverse Events Due to Immune Checkpoint Blockade

NCT04375228 is registered in ClinicalTrials.gov with Columbia University as lead sponsor.

NCT NCT04375228
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04375228 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Phase II Multicenter Study of Rituximab or Tocilizumab for Steroid-Dependent Immune-Related Adverse Events Due to Immune Checkpoint Blockade
Lead sponsor
Columbia University
Phase
Phase 2
Overall status
Active, not recruiting
Start date
September 25, 2020
Completion date
December 31, 2026
Enrollment
7 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, immune-related adverse events